TY - JOUR
TI - Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
AU - Terpos, E.
AU - Ramasamy, K.
AU - Maouche, N.
AU - Minarik, J.
AU - Ntanasis-Stathopoulos, I.
AU - Katodritou, E.
AU - Jenner, M.W.
AU - Plonkova, H.
AU - Gavriatopoulou, M.
AU - Vallance, G.D.
AU - Pika, T.
AU - Kotsopoulou, M.
AU - Kothari, J.
AU - Jelinek, T.
AU - Kastritis, E.
AU - Aitchison, R.
AU - Dimopoulos, M.A.
AU - Zomas, A.
AU - Hajek, R.
JO - Annals of Hematology
PY - 2020
VL - 99
TODO - 5
SP - 1049-1061
PB - Springer-Verlag
SN - 0939-5555, 1432-0584
TODO - 10.1007/s00277-020-03981-z
TODO - bortezomib;  dexamethasone;  ixazomib;  lenalidomide;  thalidomide;  antineoplastic agent;  boron derivative;  dexamethasone;  glycine;  ixazomib;  lenalidomide, adult;  adverse outcome;  aged;  anemia;  Article;  cancer growth;  cancer recurrence;  clinical effectiveness;  Czech Republic;  dose response;  drug effect;  drug efficacy;  drug exposure;  drug safety;  dyspnea;  female;  gastrointestinal symptom;  Greece;  heart arrhythmia;  heart failure;  human;  hypercalcemia;  kidney failure;  major clinical study;  male;  multiple myeloma;  neutropenia;  observational study;  pancytopenia;  peripheral neuropathy;  priority journal;  progression free survival;  retrospective study;  thrombosis;  treatment outcome;  United Kingdom;  clinical trial;  disease free survival;  middle aged;  mortality;  multicenter study;  multiple myeloma;  phase 3 clinical trial;  recurrent disease;  survival rate;  very elderly, Adult;  Aged;  Aged, 80 and over;  Antineoplastic Combined Chemotherapy Protocols;  Boron Compounds;  Dexamethasone;  Disease-Free Survival;  Female;  Glycine;  Humans;  Lenalidomide;  Male;  Middle Aged;  Multiple Myeloma;  Recurrence;  Survival Rate
TODO - Real-world data on regimens for relapsed/refractory multiple myeloma (RRMM) represent an important component of therapeutic decision-making. This multi-centric, retrospective, observational study conducted by the treating physicians evaluated the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in 155 patients who received ixazomib via early access programs in Greece, the UK, and the Czech Republic. Median age was 68 years; 17% had an Eastern Cooperative Oncology Group performance status ≥ 2; median number of prior therapies was 1 (range 1–7); 91%, 47%, and 17% had received prior bortezomib, thalidomide, and lenalidomide, respectively. Median duration of exposure to ixazomib was 9.6 months. Overall response rate was 74%, including 35% very good partial response or better (16% complete response). Median progression-free survival (PFS) was 27.6 months (27.6 and 19.9 months in patients with 1 or > 1 prior lines, respectively). IRd treatment for ≥ 6 months was associated with longer PFS (hazard ratio 0.06). Fourteen patients (9%) discontinued IRd due to adverse events/toxicity in the absence of disease progression. Peripheral neuropathy was reported in 35% of patients (3% grades 3–4). These findings support the results of the phase III TOURMALINE-MM1 trial in a broader real-world RRMM population. © 2020, Springer-Verlag GmbH Germany, part of Springer Nature.
ER -